NR and Exercise for Blood Pressure

Официальное название

Effects of Ten-Week Oral Nicotinamide Riboside Supplementation With Aerobic Exercises on Blood Pressure in Post- Menopausal Women With Elevated/Stage I Hypertension

Обзор

Hypertension continues to pose a significant global health challenge, with rates of optimal blood pressure control remaining low - particularly in China, where fewer than 5% of individuals with hypertension achieve guideline-recommended targets. Age-associated endothelial dysfunction and arterial stiffness are recognized as the key contributors to the development of hypertension and the unique role of nicotinamide adenine dinucleotide (NAD) depletion in the pathogenesis of vascular dysfunction has been recently discovered. Treatment with nicotinamide riboside (NR), an NAD precursor, has shown promise in preliminary clinical trials for improving blood pressure and vascular health in at-risk populations. In parallel, aerobic exercise is a well-established non-pharmacologic intervention known to improve cardiovascular outcomes. Emerging studies suggest that exercise may modulate NAD biosynthesis pathways, pointing toward a synergistic potential when combined with NAD-boosting strategies. However, clinical data evaluating the combined effects of NR supplementation and aerobic exercise remain scarce. Our randomized, placebo-controlled, four-arm, parallel-group design seeks to address this gap. The investigators will investigate the independent and combined effects of 10-week NR supplementation and brisk walking on blood pressure and vascular health in post-menopausal women with elevated/stage I hypertension. This population is specifically targeted due to their heightened risk for vascular dysfunction post-menopause and the observed responsiveness to NR-based interventions in prior studies. The investigators believe the findings from this trial will provide insight into the feasibility, safety, and efficacy of combining NAD-boosting supplementation with structured exercise in a uniquely vulnerable and previously understudied population. The potential to identify a low-risk, non-pharmaceutical therapeutic approach holds strong implications for public health, particularly in aging women with early-stage hypertension.

Вмешательства

• Поведенческое Brisk walking
  Brisk walking twice per week
• Пищевая добавка Nicotinamide Riboside 1000 mg
  Nicotinamide Riboside supplementation 1000 mg per day
• Другое Placebo
  Placebo

Первичные конечные точки

• Blood pressure [Срок оценки: From enrollment to the end of follow-up at 20 weeks]

Вторичные конечные точки (12)

• Whole Blood NAD concentration [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Endothelin 1 [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Angiotensin [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Body mass [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Fat mass [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Fat-free mass [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Fat percentage [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Height [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• BMI [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Waist Circumference [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• Seven-day accelerometry [Срок оценки: From enrollment to the end of follow-up at 20 weeks]
• 30-second chair stand test [Срок оценки: From enrollment to the end of follow-up at 20 weeks]

Критерии участия

Критерии включения

• women absent of menstruation for over one year,
• Chinese, and
• fulfill the criteria of elevated/stage I hypertension according to 2025 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (i.e., blood pressure ≥120/80 mmHg based on an average of ≥2 readings obtained on ≥2 occasions)

Критерии исключения

• presence of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders,
• a history of hysterectomy,
• current use of vitamin B supplements and/or NAD precursors,
• ongoing hormone replacement therapy within the past six months,
• any changes in antihypertensive medication type or dosage within the last three months, or
• engagement in regular physical activity, defined as at least 150 minutes of moderate-intensity exercise or 75 minutes of vigorous-intensity exercise per week, during the three months prior to enrollment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07475208 · NTEC-2025-596

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗